Document is current

Article History

Received: 24 January 2022

Revised: 2 June 2022

Accepted: 7 June 2022

First Online: 28 June 2022

Declarations

:

: The scientific guarantor of this publication is Ingfrid S. Haldorsen.

: The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

: One of the authors has significant statistical expertise.

: Written informed consent was obtained at primary diagnosis from all patients in this retrospective study on prospectively collected data.

: Institutional Review Board approval was obtained.

: Some study subjects have been previously reported in:1. Fasmer KE, Gulati A, Dybvik JA, et al (2020) Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer. Eur Radiol 30:2443–2453. 10.1007/s00330-019-06622-w2. Ytre-Hauge S, Husby JA, Magnussen IJ, et al (2015) Preoperative tumor size at MRI predicts deep myometrial invasion, lymph node metastases, and patient outcome in endometrial carcinomas. Int J Gynecol Cancer 25:459–466. 10.1097/IGC.00000000000003673. Husby JA, Reitan BC, Biermann M, et al (2015) Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients. J Nucl Med 56:1191–1198. 10.2967/jnumed.115.159913

: • retrospective• observational• performed at one institution